

June 28, 2024^(Revised)

Aurore Pharmaceuticals Private Limited: Ratings continue to remain under ISSUER NON COOPERATING category

Summary of rating action

Instrument [^]	Previous Rated Amount (Rs. crore)	Current Rated Amount (Rs. crore)	Rating Action
Long Term – Term Loan	91.72	91.72	[ICRA]BB+ (Stable); ISSUER NOT COOPERATING*; Rating continues to remain under 'ISSUER NOT COOPERATING' category
Long Term – Fund based	22.50	22.50	[ICRA]BB+ (Stable); ISSUER NOT COOPERATING*; Rating continues to remain under 'ISSUER NOT COOPERATING' category
Short Term – Fund Based/ Non-fund based Interchangeable #	(22.50)	(22.50)	[ICRA]A4+; ISSUER NOT COOPERATING*; Rating continues to remain under 'ISSUER NOT COOPERATING' category
Total	114.22	114.22	

*Issuer did not cooperate; based on best available information.; # sub-limit of long-term fund-based

[^]Instrument details are provided in Annexure-1

Rationale

ICRA has kept the ratings of Aurore Life Sciences Pvt Ltd in the 'Issuer Not Cooperating' category and its ratings have been denoted as [ICRA]BB+ (Stable)/ [ICRA]A4+; ISSUER NOT COOPERATING.

As a part of its process and in accordance with its rating agreement with Aurore Life Sciences Pvt Ltd, ICRA has been trying to seek information from the entity to monitor its performance. Despite repeated requests by ICRA, the entity's management has remained non-cooperative. In the absence of requisite information and in line with the aforesaid policy of ICRA, the ratings continued to remain in the Issuer Not Cooperating category. The ratings are based on the best available information.

Please refer to the following link for the previous detailed rationale that captures the Key rating drivers and their description, Liquidity position, Rating sensitivities: [Click here](#). ICRA is unable to provide the latest information because of non-cooperation by the entity.

Analytical approach

Analytical Approach	Comments
Applicable rating methodologies	Corporate Credit Rating Methodology Policy In Respect of Non-Cooperation by a Rated Entity Pharmaceuticals
Parent/Group support	Not applicable
Consolidation/Standalone	For arriving at the ratings, ICRA has taken a consolidated view of Aurore Life Sciences Pvt Ltd and Aurore Pharmaceuticals Pvt Ltd (Aurore Pharma). Aurore Life had a 85.33% stake in Aurore Pharma as on March 31, 2024.

About the company

Aurore Life commenced its operations in September 2016 with three independent research and development (R&D) centres in Hyderabad, targeting domestic and semi-regulated markets like Indonesia, Bangladesh, Iran and Egypt. Post R&D, the company outsources manufacturing to other companies, which has impacted its margins in the last few years. To mitigate this, Aurore Life acquired a manufacturing plant in FY2019, where it is producing intermediates and active pharmaceutical ingredient (API) for semi-regulated markets pending regulatory approvals. The facility has also received approval from the European Medical Agency (EMA) for some products. The present capacity of the facility is 388 KL. At present, Aurore Life utilises Aurore Pharma's facility for manufacturing its own products. HAPS hold a 62% equity stake in Aurore Life, while the balance is held by its promoter, Mr. Rajender Rao and few others. HAPS is held by Karuna Business Solutions LLP (Mr. Arun Kumar's family office) and Tenshi Pharmaceuticals Private Limited.

Established in 2017, Aurore Pharma is held by Aurore Life (85%) and Mr. Dayakar Mallu (15%). Aurore Pharma acquired a US FDA-approved API manufacturing plant from Mylan in H1 FY2019. In the near term, Aurore Pharma will provide contract manufacturing services to Aurore Life, Mylan and Aurobindo Pharma. Over the long term, Aurore Pharma is expected to cater to regulated markets like the US, Europe and Japan.

Key financial indicators (Audited)

Standalone	FY2021	FY2022	FY2023
Operating income	117.4	274.1	98.1
PAT	-14.1	-24.3	-20.6
OPBDITA/OI (%)	8.6%	-1.2%	-1.3%
PAT/OI (%)	-12.0%	-8.9%	-21.0%
Total outside liabilities/Tangible net worth (times)	-7.8	-5.1	-3.7
Total debt/OPBDIT (times)	15.5	-45.5	-114.9
Interest coverage (times)	0.6	-0.1	0.0

Source: Company, ICRA Research; Amount in Rs. crore

PAT: Profit after tax; OPBDIT: Operating profit before depreciation, interest, taxes and amortisation

Status of non-cooperation with previous CRA: Not applicable

Any other information: None

Rating history for past three years

Instrument	Type	Current Rating (FY2025)		Chronology of Rating History for the past 3 years				
		Amount Rated (Rs. crore)	Amount Outstanding as of Dec 31, 2022 (Rs. crore)	Date & Rating in FY 2025	Date & Rating in FY2024	Date & Rating in FY2023		Date & Rating in FY2022
				June 28, 2024	-	Mar 24, 2023	Jun 09, 2022	Apr 22, 2021
1 Term Loans	Long Term	91.72	72.62	[ICRA]BB+ (Stable) ISSUER NOT COOPERATING	-	[ICRA]BB+ (Stable); ISSUER NOT COOPERATING	[ICRA]BBB (Negative)	[ICRA]BBB+ (Stable)
2 Fund-based bank facilities	Long Term	22.50		[ICRA]BB+ (Stable) ISSUER NOT COOPERATING	-	[ICRA]BB+ (Stable); ISSUER NOT COOPERATING	[ICRA]BBB (Negative)	[ICRA]BBB+ (Stable)
3 Fund based/ Non-fund based*	Short Term	(22.50)		[ICRA]A4+ ISSUER NOT COOPERATING	-	[ICRA]A4+; ISSUER NOT COOPERATING	[ICRA]A3+	[ICRA]A2

*Interchangeable with fund based/non-fund based

Complexity level of the rated instrument

Instrument	Complexity Indicator
Term Loans	Simple
Fund-based bank facilities	Simple
Fund based/ Non-fund based*	Very Simple

The Complexity Indicator refers to the ease with which the returns associated with the rated instrument could be estimated. It does not indicate the risk related to the timely payments on the instrument, which is rather indicated by the instrument's credit rating. It also does not indicate the complexity associated with analysing an entity's financial, business, industry risks or complexity related to the structural, transactional or legal aspects. Details on the complexity levels of the instruments are available on ICRA's website: [Click Here](#)

Annexure-I: Instrument details

ISIN No	Instrument Name	Date of Issuance / Sanction	Coupon Rate	Maturity Date	Amount Rated (Rs. crore)	Current Rating and Outlook
NA	Term loans	FY2019	8.9% - 9.45%	FY2025	91.72	[ICRA]BB+ (Stable); ISSUER NOT COOPERATING
NA	Fund based	FY2021	4.5% - 11.75%	--	22.50	
NA	Fund based/ Non-fund based*	FY2021	4.5% - 11.75%	--	(22.50)	[ICRA]A4+; ISSUER NOT COOPERATING

Source: Company; *Interchangeable with fund based/non-fund based

[Please click here to view details of lender-wise facilities rated by ICRA](#)

Annexure-II: List of entities considered for consolidated analysis: Not applicable

Corrigendum

Rationale dated June 28, 2024, has been corrected with revisions as detailed below:

“Rating Approach – Consolidation” methodology in Applicable rating methodology under Analytical approach table has been removed.

ANALYST CONTACTS

Shamsher Dewan
+91 124 4545 328
shamsherd@icraindia.com

Kinjal Kirit Shah
+91 22 6114 3442
kinjal.shah@icraindia.com

Mythri Macherla
+91 22 6114 3435
mythri.macherla@icraindia.com

Kritika Jain
+91 080 4332 6415
kritika.jain@icraindia.com

RELATIONSHIP CONTACT

L. Shivakumar
+91 22 6114 3406
shivakumar@icraindia.com

MEDIA AND PUBLIC RELATIONS CONTACT

Ms. Naznin Prodhani
Tel: +91 124 4545 860
communications@icraindia.com

Helpline for business queries

+91-9354738909 (open Monday to Friday, from 9:30 am to 6 pm)

info@icraindia.com

About ICRA Limited:

ICRA Limited was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit www.icra.in

ICRA Limited




Registered Office

B-710, Statesman House 148, Barakhamba Road, New Delhi-110001

Tel: +91 11 23357940-45



Branches



© Copyright, 2024 ICRA Limited. All Rights Reserved.

Contents may be used freely with due acknowledgement to ICRA.

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website www.icra.in or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.